Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

Allworth Financial LP boosted its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 12.9% in the fourth quarter, ...

AstraZeneca PLC ADR closed 14.96% below its 52-week high of $87.68, which the company achieved on August 30th.

We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

AstraZeneca PLC (LON:AZN – Get Free Report) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of £114.82 ($144.52) and traded as high as ...

AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...

AstraZeneca PLC (AZN) reports a robust 21% revenue increase for 2024, while navigating market challenges and strategic ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently ...

AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...

AstraZeneca's ( ) flagship health equity programme - Healthy Heart Africa (HHA), marks its 10th anniversary, celebrating successfully ...

Amgen continues to be a key player in the Global Biopharmaceuticals Market. AstraZeneca PLC is a global biopharmaceutical company with a broad portfolio of products focused on treating diseases in ...